neflamapimod — Topline data
H2 2026
CervoMed expects to report topline data from its Phase 2a RESTORE trial evaluating neflamapimod in patients recovering from acute ischemic stroke in the second half of 2026.Source filing
CRVO biotech catalysts & pipeline
CERVOMED INC · Data as of 2026-09-08
Upcoming catalysts
neflamapimod — Topline data
Q1 2027
The Company also expects to report initial topline clinical data, as well as additional biomarker data, in the first quarter of 2027.Source filing
neflamapimod — Conference presentation
Oct 8–Oct 11
CervoMed will present 12-week biomarker data from the first eight participants in its ongoing Phase 2a trial in patients with nfvPPA at ISFTD, taking place October 8-11, 2026, in Philadelphia, Pennsylvania.Source filing
neflamapimod — Conference presentation
Nov 16–Nov 19
Full 12-week and initial, 24-week biomarker data from the trial will be presented at the 19th CTAD conference, taking place November 16-19, 2026, in Boston, Massachusetts.Source filing